Inhibrx Biosciences, Inc. (INBX)
NASDAQ: INBX · Real-Time Price · USD
86.35
+3.39 (4.09%)
Dec 4, 2025, 4:00 PM EST - Market closed
Inhibrx Biosciences Revenue
Inhibrx Biosciences had revenue of $1.40M in the twelve months ending September 30, 2025, down -19.26% year-over-year. In the year 2024, Inhibrx Biosciences had annual revenue of $200.00K, down -88.89%.
Revenue (ttm)
$1.40M
Revenue Growth
-19.26%
P/S Ratio
908.05
Revenue / Employee
$8,696
Employees
161
Market Cap
1.26B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 200.00K | -1.60M | -88.89% |
| Dec 31, 2023 | 1.80M | 485.00K | 36.88% |
| Dec 31, 2022 | 1.32M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionINBX News
- 21 days ago - Inhibrx Reports Third Quarter 2025 Financial Results - PRNewsWire
- 4 weeks ago - Inhibrx Announces Participation in Upcoming Scientific Conferences - PRNewsWire
- 5 weeks ago - Inhibrx: Positive Ozekibart Data For Bone Cancer Leads To Q2 2026 BLA Filing - Seeking Alpha
- 6 weeks ago - Inhibrx shares surge after bone cancer drug slows disease progression in trial - Reuters
- 6 weeks ago - Inhibrx Biosciences Reports Positive Topline Results from its Registrational Trial of Ozekibart (INBRX-109) in Chondrosarcoma and Provides Updates on Colorectal Cancer and Ewing Sarcoma Expansion Cohorts - PRNewsWire
- 6 weeks ago - Inhibrx To Host Webcast Presentation of Topline Results from its Registrational Trial of Ozekibart (INBRX-109) in Chondrosarcoma and to Provide Updates on Colorectal Cancer and Ewing Sarcoma Expansion Cohorts - PRNewsWire
- 4 months ago - Inhibrx Reports Second Quarter 2025 Financial Results - PRNewsWire
- 7 months ago - Inhibrx Reports First Quarter 2025 Financial Results - PRNewsWire